We are live on ! Find out more
BIOTW

Biotech Acquisition Company Warrant
BIOTW

Delisted

BIOTW was delisted on the 2nd of February, 2023.

Back to rankings

51 hedge funds and large institutions have $3.8M invested in Biotech Acquisition Company Warrant in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 5 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more funds holding

Funds holding: 48 → 51 (+3)

10% less capital invested

Capital invested by funds: $4.21M → $3.8M (-$414K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 5

Holders
51
Holders Change
+3
Holders Change %
+6.25%
% of All Funds
0.88%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
–
Reduced
5
Closed
–
Calls
$5.72M
Puts
–
Net Calls
+$5.72M
Net Calls Change
+$4K

Top Buyers

Rank Fund Capital Flow
1
PC
Periscope Capital
Ontario, Canada
+$5.81K
2
PCM
Prelude Capital Management
New York
+$1.09K

Top Sellers

Rank Fund Capital Flow
1
HIM
HGC Investment Management
Ontario, Canada
-$71.4K
2
BFM
Boothbay Fund Management
New York
-$1.46K
3
MC
Meteora Capital
Florida
-$298
4
UBS Group
UBS Group
Switzerland
-$84
5
Citadel Advisors
Citadel Advisors
Florida
-$82
Name Holding Trade Value Shares
Change 		Change in
Stake
RCM
1
Radcliffe Capital Management
Pennsylvania
$2.01M – – –
BFM
2
Boothbay Fund Management
New York
$633K -$1.46K -25,043 -28%
LP
3
LMR Partners
United Kingdom
$496K – – –
SCM
4
Segantii Capital Management
Hong Kong
$248K – – –
HIM
5
HGC Investment Management
Ontario, Canada
$73K -$71.4K -1,228,782 -50%
PAMP
6
Polar Asset Management Partners
Ontario, Canada
$37K – – –
AC
7
Aristeia Capital
Connecticut
$34K – – –
RA
8
Ramius Advisors
New York
$34K – – –
CCP
9
Corbin Capital Partners
New York
$28K – – –
KCM
10
Kingstown Capital Management
New York
$18K – – –
ACM
11
Atalaya Capital Management
New York
$17K – – –
QGA
12
Q Global Advisors
Texas
$15K – – –
LA
13
Linden Advisors
New York
$14K – – –
SCM
14
Shaolin Capital Management
Florida
$12K – – –
TI
15
Telemetry Investments
New York
$9K – – –
MI
16
MMCAP International
Cayman Islands
$8K – – –
SC
17
Sculptor Capital
New York
$8K – – –
TCM
18
Tenor Capital Management
New York
$8K – – –
AC
19
Antara Capital
New York
$7K – – –
RCM
20
Rivernorth Capital Management
Florida
$7K – – –
ACA
21
Arena Capital Advisors
California
$6K – – –
CH
22
CVI Holdings
Delaware
$6K – – –
PC
23
Periscope Capital
Ontario, Canada
$6K +$5.81K +100,000 New
DKCM
24
Davidson Kempner Capital Management
New York
$5K – – –
Citadel Advisors
25
Citadel Advisors
Florida
$4K -$82 -1,408 -2%
1
2

BIOTW Hedge Fund Activity: Q3 2022 in Review

51 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Biotech Acquisition Company Warrant (BIOTW) for Q3 2022, worth a combined $3.8M — down 9.8% from $4.21M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BIOTW positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 5 trimmed.

The largest buyer was Periscope Capital, opening a new position worth an estimated $5.81K. The largest seller was HGC Investment Management, cutting an estimated $71.4K.

  • 51 institutional investors held Biotech Acquisition Company Warrant (BIOTW) as of Q3 2022, up from 48 in Q2 2022.
  • Funds reported $3.8M of Biotech Acquisition Company Warrant stock for Q3 2022, down 9.8% quarter-over-quarter.
  • 3 funds opened new Biotech Acquisition Company Warrant positions in Q3 2022 and 0 closed out, a net change of +3 holders.
  • The largest Biotech Acquisition Company Warrant buyer in Q3 2022 was Periscope Capital, an estimated $5.81K added.
  • The largest Biotech Acquisition Company Warrant seller in Q3 2022 was HGC Investment Management, an estimated $71.4K sold.

Based on aggregated 13F filings for Q3 2022.